INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $382,000 | -22.4% | 25,739 | +4.5% | 0.00% | -100.0% |
| Q2 2021 | $492,000 | -99.2% | 24,625 | -99.0% | 0.00% | -98.6% |
| Q1 2021 | $59,224,000 | +22.6% | 2,566,018 | +31.2% | 0.07% | +12.5% |
| Q4 2020 | $48,321,000 | -22.8% | 1,956,302 | +29.6% | 0.06% | -36.0% |
| Q3 2020 | $62,563,000 | +61.5% | 1,509,008 | +86.6% | 0.10% | +49.3% |
| Q2 2020 | $38,736,000 | +10.8% | 808,516 | +45.6% | 0.07% | -15.2% |
| Q1 2020 | $34,971,000 | -63.8% | 555,440 | -28.7% | 0.08% | -52.1% |
| Q4 2019 | $96,602,000 | +64.9% | 779,549 | -11.7% | 0.16% | +50.0% |
| Q3 2019 | $58,568,000 | -32.7% | 882,585 | -19.3% | 0.11% | -32.9% |
| Q2 2019 | $86,979,000 | -13.8% | 1,093,108 | +21.2% | 0.16% | -18.4% |
| Q1 2019 | $100,895,000 | +2.0% | 901,976 | -8.1% | 0.20% | -14.5% |
| Q4 2018 | $98,924,000 | -28.3% | 981,483 | -10.1% | 0.24% | -8.6% |
| Q3 2018 | $138,025,000 | +95.7% | 1,092,319 | +29.9% | 0.26% | +76.0% |
| Q2 2018 | $70,533,000 | +40.1% | 840,584 | +2.7% | 0.15% | +25.9% |
| Q1 2018 | $50,340,000 | +42.3% | 818,274 | +35.2% | 0.12% | +38.1% |
| Q4 2017 | $35,371,000 | +102.8% | 605,454 | +101.5% | 0.08% | +86.7% |
| Q3 2017 | $17,438,000 | -49.9% | 300,455 | +4.5% | 0.04% | -51.6% |
| Q2 2017 | $34,797,000 | +25.3% | 287,411 | +17.0% | 0.09% | +20.8% |
| Q1 2017 | $27,772,000 | -9.0% | 245,555 | -12.5% | 0.08% | -15.4% |
| Q4 2016 | $30,503,000 | +1.5% | 280,742 | +53.7% | 0.09% | +1.1% |
| Q3 2016 | $30,058,000 | +9.8% | 182,623 | -4.8% | 0.09% | +4.7% |
| Q2 2016 | $27,378,000 | -14.5% | 191,885 | -23.1% | 0.09% | -16.5% |
| Q1 2016 | $32,037,000 | -63.6% | 249,377 | -57.7% | 0.10% | -54.8% |
| Q4 2015 | $87,947,000 | +14.2% | 588,866 | +26.8% | 0.23% | +2.2% |
| Q3 2015 | $77,021,000 | -34.5% | 464,373 | -4.7% | 0.22% | -26.9% |
| Q2 2015 | $117,663,000 | -34.6% | 487,459 | -23.6% | 0.30% | -42.3% |
| Q1 2015 | $180,006,000 | +316.3% | 638,274 | +130.3% | 0.53% | +262.3% |
| Q4 2014 | $43,241,000 | +1518.9% | 277,185 | +2356.2% | 0.15% | +1227.3% |
| Q3 2014 | $2,671,000 | – | 11,285 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |